In terms of combination of pyrotinib and trastuzumab plus chemotherapy regimens, the single‐arm phase‐II Panphila trial, which used a regimen of neoadjuvant trastuzumab and pyrotinib plus docetaxel and carboplatin, reported that 38 (55.1%) patients achieved pCR out of 69 patients with HER2‐positive early breast cancer.25 This evidence concerns the gene ERBB2 and breast cancer.